Asia Pacific Large Molecule Drug Substance Cdmo Market Size & Outlook
Related Markets
Asia Pacific large molecule drug substance cdmo market highlights
- The Asia Pacific large molecule drug substance cdmo market generated a revenue of USD 19,713.7 million in 2024.
- The market is expected to grow at a CAGR of 8.4% from 2025 to 2033.
- In terms of segment, contract manufacturing was the largest revenue generating service in 2024.
- Contract Development is the most lucrative service segment registering the fastest growth during the forecast period.
- Country-wise, Japan is expected to register the highest CAGR from 2025 to 2033.
Asia Pacific data book summary
| Market revenue in 2024 | USD 19,713.7 million |
| Market revenue in 2033 | USD 40,850.4 million |
| Growth rate | 8.4% (CAGR from 2025 to 2033) |
| Largest segment | Contract manufacturing |
| Fastest growing segment | Contract Development |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Contract Manufacturing, Contract Development |
| Key market players worldwide | Eurofins Scientific SE, WuXi Biologics (Cayman) Inc, Catalent Inc, AGC Inc, Siegfried Holding AG, Boehringer Ingelheim, FUJIFILM Holdings Corp, Samsung BioLogics, Rentschler Biopharma SE, Recipharm |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 37.9% of the global large molecule drug substance cdmo market in 2024.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 40,850.4 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Large Molecule Drug Substance CDMO Market Scope
Large Molecule Drug Substance CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | https://www.samsungbiologics.com/ |
| Recipharm | View profile | 1001-5000 | Jordbro, Stockholms Lan, Sweden, Europe | http://www.recipharm.com |
| Rentschler Biopharma SE | View profile | 501-1000 | Laupheim, Baden-Wurttemberg, Germany, Europe | https://www.rentschler-biopharma.com |
| Siegfried Holding AG | View profile | 4180 | Untere Bruehlstrasse 4, Zofingen, Switzerland, CH-4800 | https://www.siegfried.ch |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| WuXi Biologics (Cayman) Inc | View profile | 12740 | No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 | https://www.wuxibiologics.com |
| AGC Inc | View profile | 61671 | 1-5-1, Marunouchi, Chiyoda-ku, Tokyo, Japan, 100-8405 | https://www.agc.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | https://www.boehringer-ingelheim.com/ |
| Eurofins Scientific SE | View profile | 61798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | https://www.eurofins.com |
| FUJIFILM Holdings Corp | View profile | 83784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | http://www.fujifilmholdings.com |
Asia Pacific large molecule drug substance cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to large molecule drug substance cdmo market will help companies and investors design strategic landscapes.
Contract manufacturing was the largest segment with a revenue share of 71.8% in 2024. Horizon Databook has segmented the Asia Pacific large molecule drug substance cdmo market based on contract manufacturing, contract development covering the revenue growth of each sub-segment from 2021 to 2033.
It is expected to be the fastest growing market owing to various amendments made by regulatory organizations to change clinical trials evaluation standards according to global requirements and many major players are investing in Asia Pacific.
Also, factors such as high scope for cost savings, increased complexity in product designs, and growing number of biopharmaceutical companies in the region are expected to drive the Asia Pacific market.
Furthermore, availability of skilled workforce in the region at a lower cost than the U.S. is anticipated to propel market growth. Countries in Asia Pacific have large patient pool and the potential to have advanced medical expertise.
Reasons to subscribe to Asia Pacific large molecule drug substance cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific large molecule drug substance cdmo market databook
-
Our clientele includes a mix of large molecule drug substance cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific large molecule drug substance cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific large molecule drug substance cdmo market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific large molecule drug substance cdmo market size, by country, 2021-2033 (US$M)
Asia Pacific Large Molecule Drug Substance CDMO Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
